Fortress Biotech, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Net Income (Loss) per Common Share (Tables)

Net Income (Loss) per Common Share (Tables)

6 Months Ended

Jun. 30, 2026

Net Income (Loss) per Common Share

Schedule of Potentially Dilutive Securities are Excluded from the Computation of Net Income (Loss) Per Common Share



		June 30,
		2026		2025
Warrants to purchase Common Stock		5,951,817		14,309,001
Options to purchase Common Stock		—		18,896
Unvested Restricted Stock and deferred Restricted Stock		1,461,637		3,094,187
Unvested Restricted Stock units and deferred Restricted Stock units		1,911,224		2,655,703
Total		9,324,678		20,077,787

Schedule of Weighted Average Number of Shares


		Three Months Ended June 30,						Six Months Ended June 30,
($ in thousands, except share and per share amounts)		2026				2025		2026				2025
Net income (loss) attributable to common stockholders		$	(2,476)		$	13,355		$	105,889		$	640
Weighted average common shares outstanding - basic			31,791,173			26,879,380			31,666,585			26,679,106
Dilutive effect of potential common shares			—			2,944,802			5,345,115			2,502,927
Weighted average common shares outstanding - diluted			31,791,173			29,824,182			37,011,700			29,182,033

Net income (loss) per common share attributable to common stockholders - basic		$	(0.08)		$	0.50		$	3.34		$	0.02
Net income (loss) per common share attributable to common stockholders - diluted		$	(0.08)		$	0.45		$	2.86		$	0.02